Quick Answer
Bolt Biotherapeutics, Inc. reported Operating Income Loss of -$36.11 million for the year ending 2025.
- Bolt Biotherapeutics, Inc. showed an increase of +50.6% in Operating Income Loss from 2024 to 2025.
- This data is from Bolt Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$8.75 million | Q2 2020: -$11.11 million | Q3 2020: -$12.41 million | Q1 2021: -$18.43 million | Q2 2021: -$23.76 million | Q3 2021: -$23.53 million | Q1 2022: -$23.88 million | Q2 2022: -$23.06 million | Q3 2022: -$22.35 million | Q1 2023: -$18.42 million | Q2 2023: -$19.83 million | Q3 2023: -$18.18 million | Q1 2024: -$17.09 million | Q2 2024: -$22.60 million | Q3 2024: -$16.44 million | Q1 2025: -$12.12 million | Q2 2025: -$9.21 million | Q3 2025: -$7.70 million.
- Over the full 6 years of available data (2020 to 2025), Bolt Biotherapeutics, Inc.'s Operating Income Loss has grown by 26.6%.
- Historical annual values: Fiscal year 2025: -$36.11 million | Fiscal year 2024: -$73.05 million | Fiscal year 2023: -$76.20 million | Fiscal year 2022: -$90.32 million | Fiscal year 2021: -$92.79 million | Fiscal year 2020: -$49.18 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: